Autonomix Medical, Inc. (NASDAQ:AMIX) Sees Significant Growth in Short Interest

Autonomix Medical, Inc. (NASDAQ:AMIX) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 58,986 shares, an increase of 119.9% from the September 30th total of 26,830 shares. Based on an average trading volume of 282,590 shares, the short-interest ratio is currently 0.2 days. Approximately 6.4% of the company’s stock are sold short.

Autonomix Medical Trading Down 11.3%

AMIX traded down $0.23 during trading on Friday, hitting $1.81. 134,539 shares of the company’s stock traded hands, compared to its average volume of 180,146. The stock has a market capitalization of $1.76 million, a price-to-earnings ratio of -0.04 and a beta of -0.96. The company’s 50 day simple moving average is $3.82 and its two-hundred day simple moving average is $6.82. Autonomix Medical has a 12-month low of $1.81 and a 12-month high of $32.55.

Autonomix Medical (NASDAQ:AMIX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($5.02) earnings per share for the quarter, topping the consensus estimate of ($6.40) by $1.38. On average, equities analysts expect that Autonomix Medical will post -20.17 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on AMIX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Autonomix Medical in a research report on Monday. Wall Street Zen raised shares of Autonomix Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 3rd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Autonomix Medical currently has a consensus rating of “Hold” and an average price target of $42.00.

About Autonomix Medical

Autonomix Medical, Inc is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures.

Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures.